Fanconi anemia (FA) 1 is a rare disorder characterized by bone marrow failure, cancer susceptibility, congenital malformations, chromosomal instability, and cellular hypersensitivity to DNA-crosslinking agents. Genetically heterogeneous, FA is comprised of at least eleven complementation groups (1) . Nine of the corresponding genes (FANCA, B, C, D1, D2, E, F, G and L) have been identified, with the encoded protein product sequences bearing no similarity to each other, and in most cases, no obvious clues as to protein function (2) (3) (4) (5) (6) (7) (8) .
The FA protein core complex, first suggested to exist by the reciprocal coimmunoprecipitation of several FA proteins (9) (10) (11) (12) , was subsequently isolated from nuclear extracts of HeLa cells as a subcomponent of a 1.5 to 2MDa BLM-associated multiprotein complex (13) . Thus far, seven FA proteins including FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, and FANCL have been identified in this complex (13) . Evidence of FA core complex involvement in smaller BLM-independent complexes was also presented (13) , and a more recent study identified four forms of the FA protein complex in an immortalized fibroblast cell line, two of which are present in the nucleus, and two in the cytoplasm (14) .
The absence of any individual core complex protein results in loss of full complex formation and lack of monoubiquitination of the FANCD2 protein, which correlates with failure of FANCD2 to form nuclear foci in response to DNA crosslinking agents (15) . In chromatin, monoubiquitinated FANCD2 associates with BRCA2, identified as the FANCD1 protein (16) . In addition, absence of a single core complex component often results in reduced stability or altered subcellular localization of remaining complex members, particularly direct binding partners (8, 11, 12, (17) (18) (19) .
FANCE has been coimmunoprecipitated with other components of the FA protein complex (12, 19) as well as the downstream FANCD2 and FANCD1/BRCA2 proteins (12, 19) . The interaction of FANCD2 with FANCE in human cells has been shown to involve either the monoubiquitinated long form (FANCD2-L), or the nonubiquitinated short form (FANCD2-S), depending on the subnuclear fraction analyzed (12, 16) .
Using the yeast two-hybrid (Y2H) system, FANCE interactions with FANCC and FANCD2 have been shown to involve direct binding (20, 21) . FANCE has thus become a focus of interest as a connection between the core complex and other elements of the FA pathway, although its simultaneous binding to FANCC and FANCD2, providing an actual physical link, has not been demonstrated.
In this study, the role of FANCE in mediating interactions between other components of the FA pathway is tested in the yeast threehybrid (Y3H) system. Both a FANCC/FANCE/FANCF ternary interaction, indicative of a role for FANCE in complex assembly, and a FANCC/FANCE/FANCD2 ternary interaction linking another member of the core complex to the downstream components of the FA pathway, are identified. The FANCEmediated FANCC/FANCD2 interaction is also observed between endogenous proteins in human cell lines. A Y2H-based random mutagenesis strategy was developed to generate FANCE mutants with selective loss of the FANCD2, but not the FANCC, interaction for further analysis in the mammalian system.
Loss of the FANCE/FANCD2 link is associated with the absence of FANCD2 monoubiquitination and the presence of DNA-crosslinker sensitivity, indicative of the importance of this interaction to the function of the FA DNA damage response pathway.
MATERIALS AND METHODS

Bacterial and yeast strains -Escherichia coli
strains DH10Β (Invitrogen, Carlsbad, CA) or XL1-Blue (Stratagene, La Jolla, CA) were used in the construction and propagation of plasmid constructs unless otherwise indicated. E. coli was propagated in LB media at 30ºC for FANCD2 and FANCE constructs, and 37ºC for other constructs. Saccharomyces cerevisiae strain PJ69-4A (22) (ATCC, Manassas, VA) was used in the yeast twoand three-hybrid assays. Yeast was grown at 30ºC in YPDA or synthetic dropout media. Yeast vectors and expression constructs -GAL4 binding domain (BD) and activation domain (AD) constructs were generated previously (21) using vectors supplied in the Matchmaker GAL4 twohybrid systems (Clontech, Palo Alto, CA). Constructs for constitutive expression of influenza A hemagglutinin (HA)-tagged proteins were generated by excision of ORFs together with a 5' HA-tag sequence from GAL4-AD constructs made in the pGADT7 vector and insertion into the p426ADH (23) vector, which has a URA3 nutritional selection marker. Western blotting to confirm expression of GAL4-fusion or HA-tagged proteins used in analyses (data not shown) was as previously described (21) . Yeast three-hybrid (Y3H) assay -A version of the Y3H system in which a HA-tagged protein is constitutively expressed from a third vector (24) , in this case p426ADH, was used in this study. PJ69-4A was transformed first with the p426ADH constructs, followed by simultaneous cotransformation with the GAL4-AD and GAL4-BD constructs, using the lithium acetate method as described in the Matchmaker Yeast Protocols Handbook (Clontech). Cotransformants growing on both -Ade and -His selective media and controls were assayed for β-galactosidase activity by a liquid ONPG (o-nitrophenol-β-D-galactoside) sarkosyl permeabilization method (25) . Generation and screening of a randomly mutagenized AD-FANCE Y2H library -The strategy for generation and use of a library of randomly mutagenized AD-FANCE constructs is outlined in Figure 1 . Propagation of the AD-FANCE construct in the E. coli mutator strain XL1-Red (Stratagene) was performed according to the specifications of the manufacturer. Transformation of mutant AD-FANCE library into yeast strain PJ69-4A and subsequent isolation of plasmid DNA from yeast was performed as described in the Yeast Protocols Handbook of the Matchmaker system (Clontech). Western blotting to evaluate expression of AD-FANCE mutants (data not shown) was performed as previously described for the Y2H system (21) . Mammalian expression constructs -The myc-FANCE retroviral constructs were made in the pBabe-puro vector (26) . c-Myc-epitope sequence was added to the 5 'end of the ORF by polymerase chain reaction (PCR) using Pwo polymerase (Roche, Indianapolis, IN). All PCR products and linker regions were verified by DNA sequencing. pBabe-myc-FANCE mutants were generated by replacement of the pBabe-myc-FANCE ORF with ORFs excised from the pGADT7-FANCE mutant yeast constructs. Presence of mutations identified in pGADT7-FANCE was verified in the pBabemyc-FANCE constructs by DNA sequencing. Cell lines and transduction -The PA317 packaging cell line (27) was maintained in DMEM with 10% FCS. Previously described (1,5) normal (HSC93) and FA (HSC72, FA-A; HSC230, FA-B; HSC536, FA-C; HSC62, FA-D1; EUFA130, FA-E; EUFA409, FA-E; EUFA410, FA-E; EUFA121, FA-F; EUFA143, FA-G) Epstein-Barr virus (EBV)-immortalized human lymphoblastoid cell lines (LCLs) were maintained in RPMI 1640 media with 15% FCS. The EUFA409 and EUFA410 FA-E LCLs used for retroviral transduction are homozygous for the 421 C>T (R141X) mutation (5). Cell lines were grown at 37ºC with 5% C0 2 unless otherwise indicated. PA317 was stably transfected with pBabe-puro constructs using Lipofectamine with PLUS reagent (Gibco), with selection in 2ug/ml puromycin. (Sigma, St. Louis, MO) Following removal of PA317 producer lines from selection, retroviral supernatant was collected from cells grown at 34ºC, filtered through a 0.4 µm filter, and used to transduce LCLs in the presence of 8ug/ml polybrene (Sigma). LCLs were exposed to fresh supernatant twice daily for 4 days, followed by selection in 1ug/ml puromycin. Generation of FANCE antisera -The region of the FANCE ORF encoding amino acids 371 to 536 was cloned into the pGEX3X (Pharmacia) vector for generation of GST-FANCE(Cterm) fusion protein. GST fusion protein was produced in the E. coli strain JM109 by induction with isopropyl β-D-thiogalactopyranoside (IPTG). Fusion protein was purified by affinity chromatography on glutathione sepharose 4B (Amersham, Piscataway, NJ) according to the instructions of the manufacturer, and eluted protein was dialyzed against phosphate buffered saline (PBS). New Zealand White rabbits were injected with a 1:1 mixture of GST-FANCE(Cterm) fusion protein and complete Freund adjuvant, followed by monthly boosters of antigen in incomplete Freund adjuvant. The polyclonal antiserum was purified with immobilized Protein A (Pierce, Rockford, IL) according to the directions of the manufacturer, followed by depletion of antibodies directed against GST by chromatography with glutathione sepharose 4B containing immobilized GST. Antiserum specificity was validated by testing for recognition of recombinant protein and endogenous protein (58kDa) in cellular extracts from normal versus FA-E cell lines. The animal experiments were approved by the Animal Care Committee of The Hospital for Sick Children. Subcellular fractionation, whole cell extract preparation, immunoprecipitation and immunoblotting -Subcellular fractionation of LCLs was performed using the NucBuster protein extraction system (Novagen, Madison, WI). For preparation of whole cell extracts (WCEs), LCLs were washed with PBS and resuspended in NETN lysis buffer (20mM Tris-HCL pH8.0, 150mM NaCl, 1mM EDTA, 0.4% NP-40) supplemented with protease inhibitor cocktail (Roche) and 1mM sodium orthovanadate, followed by shearing with a 25 gauge needle and centrifugation at 10000xg at 4 o C for 10min. Protein concentration of clarified supernatants was determined using the Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). For immunoprecipitation, WCEs were diluted to adjust NP-40 concentration to 0.1%, antibodies were added at a concentration of 1µg/mg protein extract (for rabbit polyclonal antibodies or purified preimmune serum) or 0.8 µg/mg protein (for goat antibodies or goat control IgG) and incubated for 1 hour at 4 o C. Immobilized Protein A or G (Pierce) was then added and incubation continued overnight 4 o C, followed by three washes with NETN containing 0.15% NP-40 and addition of Laemmli sample buffer.
Antisera used in immunoprecipitation include the polyclonal anti-FANCE antibody described above, a rabbit polyclonal anti-FANCC antibody generously provided by H. Youssoufian and described previously (28) and goat anti -FANCC (C14), anti-FANCE (L21) and anti-FANCD2 (E19) antibodies (Santa Cruz, Santa Cruz, CA). WCEs, subcellular fractions, or immunoprecipitates were resolved by SDS-PAGE on 10% Tris-glycine, 7% Tris-acetate, or, for resolution of the monoubiquitinated form of FANCD2, 3-8% Tris-acetate gels (Invitrogen), and transferred to Immobilon-P membrane (Millipore, Bedford, MA). Antibodies used in Western analysis include the rabbit antibodies against FANCC and FANCE described above, and mouse antibodies against FANCD2 (FI17), c-myc (9E10) (Santa Cruz), and β-tubulin (Roche) followed by IgG-peroxidase conjugate and chemiluminescent detection (Amersham). MMC viability assay -LCLs (10 5 /ml) were seeded in 24-well plates. After 24 hours of growth, medium supplemented with MMC (Roche) was added at concentrations up to 300nM. After 8 days, cells were counted using a Coulter counter (Beckman Coulter, Fullerton, CA). Cell counts were plotted against MMC concentrations.
RESULTS
Y3H Analysis of FANCE-mediated protein interactions.
Use of the Y3H system to examine of the role of FANCE in mediating interactions between other FA proteins revealed the participation of FANCE in two ternary complexes (Table 1) . FANCE was able to mediate interaction between FANCC and FANCD2, the two proteins with which FANCE interacts directly in the Y2H system. Nutritional and LacZ reporter gene activation was observed for both AD-FANCC/BD-FANCD2 and BD-FANCC/AD-FANCD2 pairings (Table 2, Figure 2A ). The Y3H interaction was abrogated by the L554P mutation (29) in the Cterminus of FANCC (Table 2) , previously shown to disrupt the interaction and colocalization of FANCC with FANCE (12, 21) .
The HA-FANCE protein was also able to mediate an interaction between the FANCC and FANCF proteins, again with reporter activation observed for both AD-FANCC/BD-FANCF and BD-FANCC/AD-FANCF pairings (Table 3 , Figure 2B ).
Some reporter activation was observed for the BD-empty vector/HA-FANCE/AD-FANCF cotransformants, but the levels were below those seen for the BD-FANCC/HA-FANCE/AD-FANCF combination (Table 3, Figure 2B ). The L554P mutant of FANCC (29) also failed to participate in this ternary interaction.
The FANCC/FANCE/FANCD2 interaction in human cells. Following the demonstration of this ternary complex in the Y3H system, which is designed to bring heterologously expressed proteins together in large quantities, it was important to demonstrate that the interaction reflected occurrence in human cells. Consistent with the Y3H result, novel reciprocal coimmunoprecipitation of endogenous FANCC and FANCD2 proteins from a normal human lymphoblastoid cell line (LCL) was observed, as were the previously described constituent FANCC/FANCE and FANCE/FANCD2 interactions ( Figure 3A,B,C) . Only antibodies against the C-terminus of FANCD2 coimmunoprecipitated FANCE and FANCC, as shown, whereas antibodies to the N-terminus of FANCD2 failed to immunoprecipitate either protein. Absence of FANCC/FANCD2 interaction in FA-E cells is recovered by exogenous expression of FANCE with an N-terminal c-myc epitope tag (myc-FANCE) demonstrating the FANCE-dependent nature of the interaction ( Figure 3D ). Interaction was reduced or absent in FA patient-derived LCLs from complementation groups corresponding to core complex members, but maintained in a FA-D1 LCL, which is deficient for a downstream component of the pathway.
Loss of the FANCC/FANCD2 interaction accompanied loss or reduction of the FANCE/FANCD2 interaction, also consistent with mediation of the FANCC/FANCD2 interaction by FANCE ( Figure 3E) .
FANCF, which the FANCC/FANCE/FANCF Y3H interaction indicates may be proximal to the FANCE/FANCC pairing in the FA core complex, was not detected in FANCD2 immunoprecipitates from normal LCLs (data not shown). Generation of FANCE mutants with selective loss of FANCD2 interaction. To further investigate the contribution of FANCE interactions to the cellular phenotype of FA cells, a mutagenesis study of the FANCE protein was undertaken. In the absence of patient-derived missense mutants, recognizable motifs involved in protein interaction, or full sequence information from multiple species for comparison, a Y2H-based method was designed to identify randomly-mutagenized FANCE mutants with selective loss of the FANCD2 interaction, but maintenance of the FANCC interaction. A flow chart outlining this screening strategy is shown in Figure 1 . Of five mutants selected for exogenous expression in human LCLs, stable expression of three was observed. A schematic representation of these three mutants used in further analyses is shown in Figure 4A . All were unable to mediate the FANCC/FANCD2 interaction in the Y3H system, not surprising given the disruption of the FANCE/FANCD2 Y2H interaction. One mutant, FANCE-E263K, did retain the ability to participate in the FANCC/FANCE/FANCF interaction ( Figure 4B) .
Immunoblotting of subcellular fractions revealed that the two point mutants, FANCE-L348M and FANCE-E263K, were expressed in the nuclear compartment of the FA-E LCL EUFA409, as was wild type myc-FANCE. This is consistent with previous reports that FANCE, which has putative nuclear localization signals (5), localizes primarily to the nucleus (19) . The truncation mutant generated by a single base pair insertion resulting in a frameshift (FANCE-312X) was observed only in the cytoplasm ( Figure 4C ).
The ability of myc-FANCE mutants exogenously expressed in EUFA409 to restore the FANCC/FANCE/FANCD2 interaction and reconstitute elements of the FA pathway, namely monoubiquitination of FANCD2 and correction of MMC sensitivity, was also examined. Wild type myc-FANCE restored the FANCC/FANCE/FANCD2 interaction ( Figure  4D ), as well as FANCD2 monoubiquitination ( Figure 5A ) and MMC resistance, which was assayed as the viability of transduced cell lines at increasing concentrations of MMC and shown relative to the HSC93 wild-type LCL. (Figure 5B ). The FANCE-L348M mutant, shown to retain some ability to interact with FANCD2 in human LCLs ( Figure 4D ), and perhaps weakly mediate the FANCC/FANCD2 interaction, showed weak FANCD2 monoubiquitination ( Figure 5A ) and corrected MMC sensitivity, although not as fully as wild-type myc-FANCE ( Figure 5B ). Failure to detect the FANCE/FANCD2 interaction of the FANCE-L348M mutant in the Y2H screen may have been due to the lower expression level of this mutant in yeast, relative to wild type FANCE or FANCE-E263K (data not shown), and introduces the possibility that failure to detect the FANCC/FANCE/FANCF interaction was also a false-negative result. The FANCE-312X and FANCE-E263K mutants were unable to restore the FANCE/FANCD2 interaction ( Figure 4D ) or monoubiquitination of FANCD2 ( Figure 5A) , and had little effect on the poor viability of FA-E cells exposed to MMC ( Figure 5B ).
DISCUSSION
In this study we demonstrate the ability of FANCE to mediate interaction between its binding partners FANCC and FANCD2 both in yeast and human cells, and evaluate the effect of FANCE mutants with selective loss of the FANCD2 interaction on reconstitution of the FA pathway in FA-E cells. The ability of FANCE to mediate interaction between FANCC and FANCF in the Y3H system is also demonstrated.
Detection of the FANCC/FANCE/FANCF ternary interaction is interesting given that FANCF could not be shown to bind directly with either FANCC or FANCE in the Y2H system (20, 21) . The FANCC/FANCE interaction may alter the conformation of one or both partners, allowing for FANCF binding, or, alternatively, FANCF may bind to both FANCC and FANCE simultaneously, with one-on-one interaction being too unstable for detection in the Y2H system. Another possibility is that FANCE transiently interacts with, and modifies, either FANCC or FANCF in some manner, in turn allowing a direct FANCC/FANCF interaction to occur. However, the presence of these three proteins together in the larger FA core complex (13) makes this scenario less likely. Furthermore, a previous study identifying functional domains within the FANCF protein demonstrated a requirement for the FANCF Nterminus in binding of both FANCE and FANCC to the FA core complex, suggestive of ternary complex formation (30) , and indicating that FANCC/FANCE/FANCF interaction is an important step in the assembly of the larger FA core complex.
The ability of FANCE to mediate an interaction between FANCC and FANCD2 in the Y3H system is most simply explained by formation of a ternary complex in which FANCE simultaneously forms the direct interactions with FANCC and FANCD2 previously reported in Y2H studies (20, 21 The interaction of FANCE with FANCD2 maps to the N-terminus (21), thus FANCD2 bound to FANCE may not be accessible to this antibody, whereas an antibody directed against the C-terminal region of FANCD2 coimmunoprecipitated FANCE and FANCC in tandem.
Despite lack of evidence for interaction of FANCD2 with other FA core complex proteins such as FANCF, the FANCC/FANCE/FANCD2 interaction appears to be reduced in cell lines lacking these proteins. Reduced stability of FANCC or FANCE in the absence of core complex formation could be a contributing factor. The levels of both FANCF and FANCC proteins are reduced in FA-E LCLs (12, 19) , and this is corrected by exogenous expression of FANCE, suggesting that formation of the FANCC/FANCE/FANCF ternary complex may have a stabilizing effect on its components (19) . Correction of FA-A lines has also been reported to increase the expression of FANCC (10) . However, maintenance of the interaction at reduced levels in at least some core complex complementation groups suggests formation of the entire core complex is not an absolute prerequisite for the FANCC/FANCE/FANCD2 interaction.
Interaction of the FANCE-312X mutant with FANCC in the Y2H system further narrows the C-terminal boundary of the minimal region of FANCE sufficient for FANCC binding, previously defined as amino acids 150 to 371 (21) . Also interesting is the cytoplasmic localization of this mutant, despite retaining the putative NLSs. While this may suggest the motifs are nonfunctional, it is also possible that C-terminal truncation counteracts the activity of functional motifs, as is observed for the FANCA protein (31) .
A FANCE mutant (E263K) that retains the observed interactions with core complex proteins in the Y2H and Y3H systems, but not the interaction with FANCD2, did not restore FANCD2 monoubiquitination or correct MMC sensitivity when exogenously expressed in a FA-E cell line. Failure of this mutant with potential for core complex formation to reconstitute the FA pathway suggests the FANCE/FANCD2 interaction is an absolute requirement; ablation of this interaction alone may be capable of generating the FA cellular phenotype, by severing the connection between the intact complex and a downstream element of the FA pathway.
Only the FANCE-L348M mutant that retains some ability to interact with FANCD2 in LCLs was able to weakly reconstitute the FANCD2 monoubiquitination feature of the FA pathway, and partially correct the MMC sensitivity of FA-E cells. This is reminiscent of the findings of a study of patient-derived variants of the FANCA gene in which those that partially reconstituted elements of the FA pathway, including FANCD2 monoubiquitination, were able to confer some MMC resistance (32) . Previous studies have also demonstrated the failure of patient-derived missense mutants of FANCC to interact with FANCE (12, 21) . Taken together, this evidence highlights the importance of formation of the FANCC/FANCE/FANCD2 ternary complex to the function of the FA damage response pathway.
The requirement for FANCE to mediate interaction between FANCC and FANCF in the Y3H system suggests a role for this protein in the assembly of the FA complex, in addition to its interaction with FANCD2 (12, 21) and role in the subcellular localization of FANCC (12, 19 
